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Adipose-derived mesenchymal stem cells (ADMSCs) display im-
munosuppressive properties, suggesting a promising therapeutic
application in several autoimmune diseases, but their role in type 1
diabetes (T1D) remains largely unexplored. The aim of this study
was to investigate the immune regulatory properties of allogeneic
ADMSC therapy in T cell–mediated autoimmune diabetes in NOD
mice. ADMSC treatment reversed the hyperglycemia of early-onset
diabetes in 78% of diabetic NOD mice, and this effect was associ-
ated with higher serum insulin, amylin, and glucagon-like peptide 1
levels compared with untreated controls. This improved outcome
was associated with downregulation of the CD4+ Th1-biased im-
mune response and expansion of regulatory T cells (Tregs) in the
pancreatic lymph nodes. Within the pancreas, inﬂammatory cell
inﬁltration and interferon-g levels were reduced, while insulin, pan-
creatic duodenal homeobox-1, and active transforming growth
factor-b1 expression were increased. In vitro, ADMSCs induced the
expansion/proliferation of Tregs in a cell contact–dependent man-
ner mediated by programmed death ligand 1. In summary, ADMSC
therapy efﬁciently ameliorates autoimmune diabetes pathogenesis
in diabetic NOD mice by attenuating the Th1 immune response
concomitant with the expansion/proliferation of Tregs, thereby
contributing to the maintenance of functional b-cells. Thus, this
study may provide a new perspective for the development of
ADMSC-based cellular therapies for T1D. Diabetes 61:2534–
2545, 2012
Autoimmune type 1 diabetes (T1D) is an inﬂam-matory T cell–mediated autoimmune destruction ofinsulin-producing b-cells at the pancreatic islets (1).This process is mainly mediated by Th1-effector
CD4+ cells and by proinﬂammatory cytokines, such as in-
terferon (IFN)-g, interleukin (IL)-2, and tumor necrosis
factor (TNF)-a (2). Some studies show that the treatment
of nonobese diabetic (NOD) mice with anti–IFN-g anti-
body prevents the development of diabetes (3), and the
transgenic expression of this cytokine in diabetes-resistant
mice results in disease development (4). In addition, the
in vitro combination of IL-1b, IFN-g, and TNF-a has been
shown to increase the b-cell vulnerability to autoimmune de-
struction (5). The autoimmune process in T1D is also com-
posed of regulatory components, such as CD4+CD25+Foxp3+
regulatory T cells (Tregs), which are important for sup-
pressing the activation of the immune system and thereby
maintaining homeostasis and tolerance to self-antigens (6).
The reduction of Treg frequency by disrupting the B7/CD28
pathway could accelerate the onset of autoimmune di-
abetes in NOD mice (7), while the expansion of these cells
in pancreatic lymph nodes (PLNs) was correlated with
disease resistance (8). Several successful experimental
therapies for T1D show a correlation between a better
outcome and an increased frequency of these cells (9–11).
As a result of their immune suppressive/regulatory and
regenerative potential, mesenchymal stem cells (MSCs) have
emerged as a potential new therapy for T1D. Several studies
from the past few years show that MSCs are capable of
suppressing the immune response by inhibiting the maturation
of dendritic cells and suppressing the proliferation/function
of T cells, B cells, and NK cells (12–15). Moreover, MSCs have
been shown to induce the expansion of CD4+CD25+Foxp3+
Tregs (16–18), and some studies evaluate the therapeutic
effect of allogeneic or syngeneic bone marrow–derived
MSCs in the prevention or reversion of autoimmune di-
abetes in several experimental models (19–26). It is im-
portant that adipose-derived (AD)MSCs, which can be
isolated from fat tissue after liposuction and easily ex-
panded in culture, have become an attractive source of
MSCs for cell therapy. In addition, it has been shown that
ADMSCs can suppress in vivo T-cell autoimmune responses
in graft-versus-host disease and some experimental models
of autoimmune diseases, such as collagen-induced arthritis,
experimental colitis, and autoimmune encephalomyelitis
(27–29). However, the immunosuppressive effect of ADMSCs
in the treatment of T1D remains largely unexplored. In
this study, we evaluated the therapeutic potential of
ADMSCs in ameliorating the recent onset of experimental
autoimmune diabetes in a NOD mouse model with regard
to their immune regulatory properties. Therefore, we in-
vestigated the potential of ADMSC therapy to simulta-
neously suppress the Th1 CD4 T cell–mediated immune
response involved in this disease and promote the expansion
of Tregs.
RESEARCH DESIGN AND METHODS
NOD (H2-Ag7) mice were purchased from Taconic (Germantown, NY), and
Balb/c mice (H2-Ad) were purchased from The Jackson Laboratory (Bar
Harbor, ME). Professor Alexandre Salgado Basso (Universidade Federal de
São Paulo) provided the C57BL/6 Foxp3-GFP knock-in mice. All protocols
were conducted in adherence to the Brazilian Committee for Experimental
Animals and were approved by the institutional ethics committee on animal
use of the University of São Paulo.
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Isolation and characterization of ADMSCs. ADMSCs were isolated from
epididymal fat tissue from 8-week-old male Balb/c mice (n = 10) and char-
acterized by immunophenotyping (Supplementary Fig. 1E), potential of multi-
lineage differentiation (Supplementary Fig. 1B–D), and ability to inhibit the
proliferation of CD4+ T cells (Supplementary Fig. 1F) in agreement with
previous studies (30,31).
Experimental autoimmune diabetes in NOD mice and treatment
protocol. To study the immunomodulatory properties of ADMSCs, we used
the model of experimental spontaneous autoimmune diabetes in NOD mice
(32). Blood glucose levels were monitored once a week with an Accu-Chek
Advantage glucometer (Roche, Mannheim, Germany) in female NOD mice
from age 12 to 30 weeks under nonfasting conditions. The mice were con-
sidered diabetic when blood glucose levels were .240 mg/dL for at least two
sequential determinations (day 0) (24). The incidence of diabetes at age 30
weeks reached 75%. For the treatment of animals, 1 3 106 ADMSCs were
suspended in 0.2 mL PBS and administrated by intraperitoneal injection in
female NOD diabetic mice (n = 9) on days 0, 7, and 14. At the same time,
a control group of diabetic mice (n = 7) was injected with PBS. The mice from
the same offspring that did not develop diabetes (hyperglycemia) were used as
controls (normoglycemic control group) (n = 5). Blood glucose levels were
determined once a week after treatment, and the animals were killed on day
35 (short-term experiment). In the long-term experiment (n = 9, ADMSC-
treated group; n = 15, untreated diabetic group), the mice were killed 12
weeks after the ﬁrst ADMSC administration.
Intraperitoneal glucose tolerance test. The peripheral response to glucose
was evaluated by the intraperitoneal glucose tolerance test (IGTT) 32 days after
the ﬁrst ADMSC injection. The glucose (1.5 mg/g body wt) was administrated
intraperitoneally in 12-h fastingmice, and blood glucose levels were determined
before and 15, 30, 60, 90, and 120 min after glucose administration.
Histology and immunohistochemistry. For pancreas histology, parafﬁn-
embedded sections of 5 mm in size were stained by hematoxylin-eosin (H-E),
and the extent of inﬂammatory cell inﬁltration (or insulitis score) into the
pancreatic islets was evaluated. Furthermore, immunohistochemical staining
was performed using anti-mouse insulin (1:400, C27C9; Cell Signaling Tech-
nology, Danvers, MA) and anti-mouse pancreatic duodenal homeobox-1 (PDX-1)
(1:500, ab47267; Abcam, Cambridge, MA) antibodies. The reaction was deve-
loped using the Envision Dual Link System-HRP kit (Dako, Glostrup, Denmark)
according to the manufacturer’s recommendations.
Intracellular cytokine analysis and Foxp3 staining. Cells were obtained
from pancreatic PLNs and analyzed by ﬂow cytometry for surface markers CD4
(PerCP) and CD25 (ﬂuorescein isothiocyanate) and afterward for intracellular
transcription factor Foxp3 using allophycocyanin anti-mouse/rat Foxp3
staining (eBioscience, San Diego, CA). For intracellular cytokine staining with
allophycocyanin-conjugated anti–TNF-a and ﬂuorescein isothiocyanate-conjugated
anti–IFN-g antibodies, the BD Cytoﬁx/Cytoperm Fixation/Permeabilization solution
kit (BD Biosciences) was used according to the manufacturer’s recommendations.
Cytokine levels in serum and pancreatic tissue. The levels of IL-2, IFN-g,
and TNF-a cytokines in the serum and pancreatic tissue homogenate were
quantiﬁed using a Bio-Plex cytokine assay kit according to the manufacturer’s
recommendations (Bio-Rad Laboratories, Hercules, CA).
Hormone levels. The blood was obtained by intracardiac puncture of anes-
thetized nonfasting mice before theywere killed on day 35. The levels of glucagon-
like peptide 1 (GLP-1) (active), glucose-dependent insulinotropic polypeptide
(GIP) (total), peptide YY (PYY) (total), amylin (active), leptin, and insulin were
FIG. 1. ADMSC treatment attenuates hyperglycemia of early-onset autoimmune diabetes in NOD mice. ADMSCs (1 3 106) were administrated by
intraperitoneal injection in female NOD diabetic mice (blood glucose >240 mg/dL by two consecutive measurements) on days 0, 7, and 14. A: Blood
glucose (mg/dL) was measured in nonfasting mice once a week after treatment for 28 days, and the mice were killed on day 35. Black lines indicate
mice that showed a reduction in blood glucose levels after treatment (n = 7). A reduction in blood glucose levels was observed mainly on day 21
after the ﬁrst ADMSC injection. Gray lines indicate mice that did not show a reduction in blood glucose levels after treatment (n = 2). B: Blood
glucose levels in the untreated group: a group of diabetic mice was treated with PBS (n = 7) on the same days of ADMSC administration as in the
treated group. The gray region denotes blood glucose values <240 mg/dL. Average 6 SEM of the blood glucose levels in the initiation of treatment
is shown and did not differ between groups (P = NS). C: Area under the curve of blood glucose levels from day 1 to 28. The area under the curve was
determined for each animal, and the average 6 SD of each group is shown. D: Blood glucose levels (mg/dL) at 12 h of fasting were determined 32
days after treatment, and lower levels were detected in ADMSC-treated mice as compared with the untreated group. Data are average 6 SD. **P<
0.01, ***P < 0.0001.
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quantiﬁed in serum samples using the Mouse Gut Multiplex Assay Kit (Millipore,
Billerica, MA).
Homing of ADMSCs. To study the in vivo homing of ADMSCs, cells were
labeled for 10 min at 37°C with 5 mmol/L 5,6-carboxyﬂuorescein diacetate
succinimidyl ester (CFSE; Molecular Probes, Eugene, OR). A total of 2 3 106
cells were intraperitoneally injected into diabetic NOD mice. The CFSE+ cells
in the spleen, pancreas, peritoneal cavity, and PLNs were analyzed by ﬂow
cytometry or immunoﬂuorescence microscopy 18 and 72 h after cell injection.
Age-matched untreated female NOD mice were used to verify and establish
the basal tissue autoﬂuorescence.
Enzyme-linked immunosorbent assay for TGF-b1. An ELISA (TGFb1 Emax;
Promega, Madison, WI) was used to measure the amount of TGF-b1 protein in
pancreatic tissue lysates and conditioned media according to the manu-
facturer’s recommendations.
In vitro expansion/proliferation of Foxp3+ cells by ADMSCs. To evaluate
the in vitro expansion of CD4+CD25+Foxp3+ cells induced by ADMSCs, CD4+ T
cells were isolated from the spleen of Foxp3-GFP C57BL/6 knock-in mice using
CD4 microbeads (L3T4; Miltenyi Biotec, Auburn, CA). CD4+ T cells (1 3 106)
were cocultured with ADMSCs (1 3 105 cells) in a six-well plate (cell-to-cell
contact) or in a transwell system (Millipore) (ADMSCs in the upper chamber
and CD4+ cells in the bottom chamber) in the presence of IL-2 (50 units/mL).
Where indicated, an anti–programmed death ligand 1 (PD-L1) neutralizing
antibody (clone 10F.9G2; Biolegend) or isotype control was used at 5 mg/mL.
Cell proliferation was veriﬁed using the CellTrace Violet Cell Proliferation Kit
(Molecular Probes). The frequency and proliferation of CD25+Foxp3+ cells in
the CD4+ T-cell gate were analyzed by ﬂow cytometry after 4 days.
Statistical analysis. Differences among groups were compared using ANOVA
(Tukey posttest) or Student t test. All statistical analyses were performed using
GraphPad PRISM 4 software, and the differences were considered signiﬁcant
at P , 0.05.
RESULTS
ADMSC treatment attenuates hyperglycemia of early-
onset autoimmune diabetes. Blood glucose levels were
monitored once a week in female NOD mice from age 10 to
30 weeks under nonfasting conditions. When their blood
FIG. 2. Improvement of the peripheral response to glucose and glucosuria after treatment with ADMSCs. A: An IGTT was performed in 12-h fasted
mice 32 days after the ﬁrst ADMSC administration. Glucose was administrated intraperitoneally in mice, and blood glucose levels (mg/dL) were
determined 0, 15, 30, 60, 90, and 120 min after administration. B: The area under the curve corresponding from time 0 to 120 was determined for
each animal, and the average 6 SD of each group is shown. C: Glucosuria (mg/dL) levels were determined 28 days after treatment in urine samples
using a glucometer (averages 6 SD are shown). Urine was diluted in 0.9% NaCl to ﬁt samples into the linear range of the glucometer system.
Administration of ADMSCs promotes an increase in hormone levels, which contributes to the amelioration of diabetes. Blood was obtained by
intracardiac puncture of anesthetized mice before they were killed on day 35 (n = 5 mice/group). The levels of insulin (D), amylin (pg/mL) (E),
GLP-1 (pg/mL) (F), GIP (pg/mL) (G), leptin (ng/mL) (H), and PYY (pg/mL) (I) are shown, and all data are expressed as average 6 SEM. *P< 0.05,
**P < 0.01, ***P < 0.001.
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glucose levels were .240 mg/dL after two consecutive
determinations, 1 3 106 ADMSCs (ADMSC-treated group)
or PBS (untreated group) were injected intraperitoneally
on days 0, 7, and 14 into the NOD mice. It is important that
the blood glucose measurements upon initiation of treat-
ment did not differ between groups (P = NS). The ADMSC
treatment reversed the hyperglycemia of early-onset di-
abetes in NOD mice in 78% (seven of nine) of the animals
by 28 days after the treatment. The blood glucose levels in
nonfasting mice were lower in the ADMSC-treated group
compared with those of the untreated diabetic mice, which
remained hyperglycemic throughout the entire period stud-
ied (Fig. 1A–C). To better evaluate the hyperglycemia at-
tenuation promoted by ADMSC treatment, the 12-h fasting
blood glucose levels were determined 32 days after treatment.
It is interesting that in the ADMSC-treated mice, the fasting
blood glucose levels were lower compared with those of
the nontreated mice (147.8 6 70.9 vs. 467.0 6 42.4 mg/dL,
P , 0.001) (Fig. 1D). Moreover, ADMSC-treated mice did
not lose weight, indicating lower morbidity caused by the
disease (data not shown).
Improvement of the peripheral response to glucose
and glucosuria after treatment with ADMSCs. To
evaluate the peripheral response to glucose, an IGTT was
performed after ADMSC treatment in ADMSC-treated, un-
treated, and normoglycemic NOD mice. The ADMSC-
treated mice showed a signiﬁcant improvement in response
to intraperitoneal glucose administration (Fig. 2A), and a
statistically signiﬁcant difference was observed when
comparing the area under the curve of the IGTT among the
FIG. 3. ADMSC therapy reduces inﬂammatory cellular inﬁltrate and improves insulin and PDX-1 expression in pancreatic islets. A: Histological
analysis of the pancreas by H-E and immunohistochemistry for insulin and PDX-1 expression, respectively. Original magniﬁcation 3400.
B: Quantiﬁcation of mononuclear cellular inﬁltrate (or insulitis score) in the pancreatic islets was determined by counting approximately 60 islets/
experimental group from at least ﬁve mice/group using the following classiﬁcation: 0 (no cellular inﬁltration), 0–25, 25–50, >50, and 100% of cell
inﬁltration in each islet. C: The positive area for insulin in the pancreatic islets was quantiﬁed using the imaging software NIS-Elements AR 3.2
(Nikon). Data are average of % insulin positive area/squared pixels (px2) 6 SEM. *P < 0.05. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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treated and untreated mouse groups (Fig. 2B). In addition,
the glucose levels in the urine samples were lower in the
treated mice compared with the nontreated mice (Fig. 2C).
As shown in Fig. 2D, the serum insulin levels of ADMSC-
treated mice were signiﬁcantly higher than those of the
untreated mice (552.2 6 186.0 vs. 198.5 6 38.14 pg/mL,
respectively, P , 0.05) and similar to the normoglycemic
control group (462.6 6 85.85 pg/mL).
Administration of ADMSCs promotes an increase in
some hormone levels reﬂective of autoimmune dia-
betes improvement. The levels of amylin, a peptide
hormone secreted with insulin by pancreatic b-cells, were
higher in the treated mice than in the untreated mice
(65.336 8.27 vs. 29.436 7.54 pg/mL, P, 0.05) (Fig. 2E). In
addition, the ADMSC treatment signiﬁcantly increased
serum GLP-1 levels (104.5 6 25.98 in treated mice vs.
38.82 6 7.55 pg/mL in untreated mice) (Fig. 2F).
Treatment with ADMSCs reduces the amount of
inﬂammatory cell inﬁltration and maintains insulin
expression in pancreatic islets. To evaluate the ability
of ADMSC treatment to reduce the inﬂammatory cell in-
ﬁltration in pancreatic islets (insulitis), the following
groups were analyzed: 1) female NOD mice at age 6 weeks,
2) normoglycemic female NOD mice at age 12 weeks, 3)
untreated diabetic mice, and 4) ADMSC-treated mice. The
analysis of groups 1, 2, and 3 showed a spontaneous in-
crease in insulitis with the age of NOD mice (Fig. 3B).
In the pancreatic islets of the untreated diabetic mice,
a severe insulitis score was found. In most of the islets
analyzed (44.6%), the cell inﬁltration covered the pancre-
atic islets entirely (score of 100% for insulitis) (Supple-
mentary Fig. 2 and Fig. 3A and B). It is noteworthy that the
ADMSC-treated mice showed a signiﬁcant reduction in
insulitis compared with the untreated group (P , 0.0001)
because a large number of islets had no cellular inﬁltration
or peri-insulitis (63.0% of analyzed islets for ADMSC-treated
mice vs. 14.0% of analyzed islets for untreated mice) (Sup-
plementary Fig. 2 and Fig. 3A and B).
Because ADMSC therapy could reduce the inﬂammatory
cellular inﬁltrate, it was interesting to analyze the expres-
sion of insulin and PDX-1 in pancreatic islets, which reﬂect
the maintenance/survival of functional b-cells, in treated
mice. The islets from ADMSC-treated mice showed a
higher expression of insulin compared with the untreated
diabetic mice and were similar to the normoglycemic
control group (P , 0.05) (Fig. 3A and C). Moreover, the
PDX-1 staining of the islets from the treated mice was
more similar to that observed in the normoglycemic control
animals, while in the untreated mice, PDX-1 expression was
barely detected (Fig. 3A).
Modulation of the CD4+ Th1 immune response in
PLNs. Considering that autoimmune diabetes is charac-
terized by a Th1 immune response, we evaluated whether
ADMSC treatment could attenuate the high levels of IFN-g
and TNF-a produced by CD4+ T cells in the PLNs of the
diabetic NOD mice. The frequency of both CD4+IFN-g+
and CD4+TNF-a+ T cells was lower in ADMSC-treated
mice compared with the untreated group (Fig. 4A and B).
To study the in vivo homing capacity of ADMSCs, the cells
were CFSE-stained and then administered to diabetic NOD
mice by intraperitoneal injection. It is noteworthy that
ADMSCs expressed chemokine receptors (Supplementary
Fig. 3A) and that CFSE+ cells were detected in the peritoneal
cavity, pancreas, and PLNs 72 h after administration (Sup-
plementary Fig. 3).
Therapy with ADMSCs increases the frequency of
CD4+CD25+Foxp3+ T cells in the PLNs. To evaluate the
hypothesis that the therapeutic effect of ADMSC treatment
FIG. 4. ADMSC treatment modulates the Th1 immune response by decreasing CD4+IFN-g+ and CD4+TNF-a+ T cells in the PLNs of diabetic mice.
The cells obtained from the PLNs were stimulated in vitro with phorbol-12-myristate-13-acetate (100 ng/mL) + ionomycin (1 mg/mL) and brefeldin
A (1 mg/mL) for 5 h and after analysis by ﬂow cytometry for intracellular cytokine staining. Dot plots represent CD4+IFN-g+ (A) and CD4+TNF-a+
(B) T-cell frequencies in the CD4+ cell gate. Graphs show frequency of CD4+IFN-g+ and CD4+TNF-a+ T cells in PLNs in the CD4+ cell gate and
absolute number of CD4+IFN-g+ and CD4+TNF-a+ T cells in the PLNs. Normoglycemic (control), female NOD from the same offspring that did not
develop diabetes (hyperglycemia), used as controls (n = 5); Untreated, diabetic untreated mice (n = 5); ADMSC-treated, group of diabetic mice
treated with ADMSCs (n = 5). Data are average 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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could be associated with the expansion of Tregs, we an-
alyzed the frequency of CD4+CD25+Foxp3+ T cells in
the PLNs of treated mice compared with that of both
the untreated and normoglycemic mice. The frequency
and absolute numbers of CD4+CD25+Foxp3+ T cells were
higher in the PLNs of treated mice than those of the un-
treated mice (12.55 6 1.22 vs. 5.96 6 1.12%, P , 0.01)
(Fig. 5).
In vitro expansion of CD4+CD25+Foxp3+ induced by
ADMSCs is partially dependent on cell-to-cell contact
and mediated by PD-L1 costimulatory molecule. Be-
cause ADMSC treatment promoted an increase in the fre-
quency of CD4+CD25+Foxp3+ T cells in PLNs, we evaluated
the in vitro expansion of these cells in the presence of
ADMSCs. As shown in Fig. 6, both a higher frequency
(Fig. 6A and B and Supplementary Fig. 4) and prolif-
eration (Fig. 6D and E) of CD4+CD25+Foxp3+ T cells
were observed after coculture of CD4+ T cells with
ADMSCs (cell-to-cell contact) compared with CD4+ T cells
cultured alone. This effect was accompanied by higher ac-
tive TGF-b1 levels (P , 0.01) (Fig. 6C) and could be par-
tially reversed by culturing cells in a transwell system,
indicating that cell-to-cell contact mediated this process
(Fig. 6).
Recent studies identify a role for PD-L1 in the de-
velopment, maintenance, and function of Tregs (33,34). It
is interesting that PD-L1 is expressed at high levels by
ADMSCs (Fig. 6F). Therefore, we hypothesized that PD-L1
could mediate the expansion of CD4+Foxp3+ T cells
induced by ADMSCs. Blocking PD-L1 impaired the ex-
pansion of CD4+Foxp3+ T cells exposed to ADMSCs (Fig.
6G and H) in a dose-dependent manner (Supplementary
Fig. 5), thereby indicating a role for this negative costimulatory
molecule in the expansion/maintenance of Tregs induced
by ADMSCs.
ADMSC treatment suppresses the Th1 immune re-
sponse in the pancreas and promotes the high expres-
sion of active TGF-b1. The levels of Th1 proinﬂammatory
cytokines IL-2, IFN-g, and TNF-a in the pancreatic tissue
lysate were determined. A major reduction was observed
in IFN-g cytokine levels (3.2 6 0.89 pg/100 mg of total
protein for the ADMSC-treated group vs. 21.33 6 6.38
pg/100 mg of total protein for the untreated group, P, 0.05)
(Fig. 7B).
TGF-b1 is a suppressor cytokine associated with an
improvement of the autoimmune response in T1D. In-
creased levels of biologically active TGF-b1 were observed
in the pancreas of ADMSC-treated mice compared with
those of both untreated mice (6,183 6 184 vs. 3,590 6 217
pg/100 mg of total protein, P , 0.001) and normoglycemic
control mice (3,956 6 232 pg/100 mg of total protein, P ,
0.001) (Fig. 7D).
ADMSC therapy maintains long-term reversion of
hyperglycemia in diabetic NOD mice. Initially, our aim
was to evaluate the short-term immune regulatory effect of
ADMSCs in the treatment of experimental autoimmune
diabetes. However, it was also important to evaluate the
maintenance of this protective effect over long periods.
FIG. 5. Therapy with ADMSCs increases the frequency of Tregs in PLNs of diabetic ADMSC-treated mice. Frequency of CD4+CD25+Foxp3+ T cells
was analyzed by ﬂow cytometry in cells obtained from the PLNs. The cells were stained for surface markers CD4 and CD25 and afterward for
transcription factor Foxp3. A–C: The frequency of CD4+CD25+, CD4+Foxp3+, and CD4+CD25+Foxp3+ T cells in the CD4+ cell gate, respectively, for
each group (n = 5/group).D–F: Absolute numbers of CD4+CD25+, CD4+Foxp3+, and CD4+CD25+Foxp3+ T cells regarding total number of cells in the
PLNs were determined for each experimental group. Data are average 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Thus, ADMSC-treated mice were followed for 12 weeks
after treatment. All untreated control mice had hypergly-
cemia during the entire monitored period (Fig. 8A). It is
noteworthy that the reversion of hyperglycemia was
maintained for 8 weeks in 78% (seven of nine) of the
ADMSC-treated mice (Fig. 8B). The weekly mean blood
glucose levels of the responder mice were signiﬁcantly
reduced compared with the untreated group from 2 to 12
weeks after the initial treatment (Fig. 8B and C). ADMSC-
treated mice also showed a signiﬁcant reduction in insulitis
and a higher expression of insulin in their pancreatic islets
compared with the untreated group at 12 weeks after
treatment (Fig. 8C and D, respectively). In addition, a higher
frequency of CD4+CD25+Foxp3+ cells was found in the
PLNs of ADMSC-treated mice compared with those of the
untreated controls (Fig. 8E–G).
Helios has recently been suggested as a potential marker
for thymic-derived natural Tregs, regarding its absence of
expression in induced Foxp3+ Tregs (35). It is important
that ADMSC-treated mice showed a higher frequency of
FIG. 6. In vitro, ADMSCs promote the expansion/proliferation of CD4+CD25+Foxp3+ T cells in a cell-to-cell contact-dependent manner in
a mechanism mediated by PD-L1. A and B: In vitro expansion/proliferation of CD4+CD25+Foxp3+ cells by ADMSCs. CD4+ T cells were isolated from
the spleen of Foxp3-GFP C57BL/6 knock-in mice and cocultured together (cell-to-cell contact) or in a transwell system with ADMSCs (10 CD4+:1
ADMSC). The frequency of putative Tregs is shown as CD4+CD25+Foxp3+ cells in the CD4+ T-cell gate. C: Active TGF-b levels were
quantiﬁed by enzyme-linked immunosorbent assay in the conditioned mediums and are shown as average 6 SEM. D: CD4+CD25+Foxp3+
T-cell proliferation was veriﬁed using Cell Trace Violet staining. The percentage of CD4+CD25+Foxp3+ divided cells after 4 days is shown
by density plot representation. E: Histogram analysis showing the proliferation of CD4+CD25+Foxp3+ T cells in the presence or absence of
ADMSCs. F: PD-L1 expression by ADMSCs. Expression of PD-L1 was veriﬁed in ADMSCs by ﬂow cytometry, and the frequency and median
intensity of ﬂuorescence (MFI) are shown. G: CD4+ T cells were cocultured with ADMSCs in the presence of anti-PD-L1 neutralizing anti-
body (clone 10F.9G2) or isotypic control. H: Frequency of CD4+Foxp3+ cells of three independent experiments is shown (average 6 SEM).
*P < 0.05, **P < 0.01.
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CD4+Foxp3+Helios+ cells in the PLNs (Fig. 8H–J and
Supplementary Fig. 6), indicating that the Foxp3+ Treg
subpopulation that was increased after ADMSC treatment
could be derived from natural thymic-derived Tregs. Taken
together, these results demonstrate an efﬁcient long-term
immune regulatory effect of ADMSCs in the treatment of
recent-onset autoimmune diabetes in NOD mice.
DISCUSSION
Over the past few years, the incidence of T1D has in-
creased, making this disease an important public health
challenge worldwide (36,37). This fact has stimulated the
research of new, safe, and effective therapies that could
control/reverse or even prevent the disease onset. In this
regard, cell-based therapies have become promising
alternatives for the prevention/treatment of T1D. Human
pancreatic islet transplantation provides a promising
treatment for T1D; however, the lack of sufﬁcient donors,
high costs, and long-term immunosuppression limit the
widespread use of this approach (38,39). Previous clinical
studies suggest that moderate immunosuppression in
newly diagnosed T1D can both prevent further loss of
insulin production and reduce insulin needs later. In this
regard, hematopoietic stem cells have been shown to have
immunomodulatory potential, and the transplantation of
these cells after immunosuppression in newly diagnosed
T1D patients has been shown to improve b-cell function
(40).
During T1D onset, residual b-cells still produce insulin,
thus providing an opportunity for therapeutic intervention
to stop/attenuate the autoimmune destruction and rescue
the b-cell function. The MSCs regulate the immune and in-
ﬂammatory responses, mainly through suppressive effects,
and thereby provide therapeutic potential for immune
intervention in several autoimmune diseases, including
T1D (41). Recently, clinical trials evaluating the effects
FIG. 7. ADMSCs attenuate the Th1 immune response in the pancreas and promote high expression of active TGF-b1. The levels of IL-2 (A), IFN-g
(B), and TNF-a (C) were quantiﬁed in pancreatic tissue homogenate. The normalization between samples was performed using the total protein
content, and the results were expressed by cytokine levels (pg)/100 mg of total protein. D: Total and biologically active TGF-b1 levels in
pancreatic tissue homogenates were detected by enzyme-linked immunosorbent assay (n = 5). Results show TGF-b1 (pg)/100 mg of total
protein (average 6 SEM). Normoglycemic (control), female NOD from the same offspring that did not develop diabetes (hyperglycemia),
used as controls; Untreated, diabetic untreated mice; ADMSC-treated, group of diabetic mice treated with ADMSCs. Data are average 6
SEM. *P < 0.05, ***P < 0.001.
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of MSCs have been initiated for several diseases, in-
cluding T1D; however, more preclinical studies evalu-
ating the safety, feasibility, and efﬁcacy of their use are
necessary. In addition, the mechanisms of immune
regulation by MSCs in autoimmune diseases have only
begun to be elucidated. The NOD mouse is an experi-
mental model quite similar to human T1D, in which
a combination of immune cell dysfunction and the
presence of the Th1 proinﬂammatory autoimmune re-
sponse leads to a failure of immune tolerance to b-cells
(42). Previous studies show the immunosuppressive
effect of ADMSCs on Th1 immune responses combined
with an expansion of Tregs in other models of autoim-
mune diseases, such as multiple sclerosis, rheumatoid
arthritis, and colitis (27–29). Herein, we hypothesized
that ADMSCs would ameliorate the recent onset of auto-
immune diabetes in NOD mice by downregulating the
CD4+ Th1 proinﬂammatory immune response concomi-
tant with the expansion of Tregs. Although previous
studies using allogeneic or syngeneic/congeneic bone
marrow–derived MSCs successfully treated autoimmune
diabetes in the NOD mouse model (21–24), the therapeutic
potential of ADMSC treatment for autoimmune diabetes,
with regard to their immune regulatory effects, was previ-
ously unexplored.
Fiorina et al. (21) showed that allogeneic bone marrow–
derived MSCs homed to the PLNs and reversed hyper-
glycemia when administered to diabetic NOD mice. It is
interesting that autologous NOD bone marrow–derived
MSCs did not result in a therapeutic beneﬁt and even
caused the formation of soft tissue and visceral tumors.
Therefore, we decided to use allogeneic ADMSCs, although
the beneﬁts of treatment with syngeneic/congeneic ADMSCs
cannot be ignored. However, although allogeneic MSCs are
considered immune-privileged cells, thereby avoiding or
suppressing the immunological responses, it is important to
note that the long-term recognition and rejection of these
cells by the immune system cannot be disregarded.
In our study, a reduction in fasting blood glucose levels,
improvement in the IGTT, and higher levels of insulin were
observed in the serum of ADMSC-treated mice. Moreover,
a decrease in the insulitis score accompanied by higher
expression of insulin and PDX-1 in pancreatic islets was
also observed, thereby indicating the maintenance of func-
tional b-cells. It is noteworthy that higher levels of hor-
mones that contribute to the amelioration of T1D, such as
amylin, leptin, and GLP-1, were observed in ADMSC-
treated mice. Amylin is a peptide hormone secreted by
b-cells simultaneously with insulin, and this hormone has
been shown to improve long-term glycemic control in
patients with T1D (43). The combination of GLP-1 and
gastrin can restore normoglycemia in diabetic NOD mice
by concomitantly increasing the pancreatic b-cell mass
and downregulating the autoimmune response (44). It
recently was observed that GLP-1 receptor signaling can
regulate lymphocyte proliferation and maintain periph-
eral Tregs in NOD mice (45). In our study, we observed
higher levels of both GLP-1 expression and Treg fre-
quency in ADMSC-treated mice, suggesting that these
factors have a role in the improvement of the recent-on-
set autoimmune diabetes observed after treatment.
In other experimental models of autoimmune diseases,
such as arthritis and colitis, treatment with ADMSCs has
been shown to modulate the CD4+ immune response
(27,46). In a model of inﬂammatory bowel disease, the
treatment of colitic and septic mice with human or murine
ADMSCs, intraperitoneally injected, signiﬁcantly reduced
the severity of the disease by abrogating body weight loss,
diarrhea, and inﬂammation. This therapeutic effect was
associated with the downregulation of the Th1 inﬂam-
matory response in the mucosa and draining lymph nodes
and the induction of Tregs, which reduced the inﬁltration
of inﬂammatory cells in various organs targeted by sepsis
(28,46). Tregs are essential in the protection/attenuation of
organ-speciﬁc autoimmune T1D. Weber et al. (47) showed
that the transfer of Tregs resulted in the prevention of T1D
in NOD mice by inhibiting the inﬂammatory cell inﬁltrate
in the pancreas and blocking the onset of disease by Th1
effector cells in the PLNs. Madec et al. (22) studied the
prevention of spontaneous insulitis after the injection of
allogeneic bone marrow–derived MSCs in 4-week-old
female NOD mice. They observed that the MSCs migrated
to the PLNs and prevented autoimmune b-cell destruction
and, therefore, T1D by inducing IL-10–secreting Foxp3+
T cells (22). In our study, the ADMSCs were detected in
the pancreas and PLNs 72 h after administration, and a
higher frequency of Tregs as well as a diminished fre-
quency of both CD4+IFN-g+ and CD4+TNF-a+ cells were
observed in the PLNs of ADMSC-treated mice. It is im-
portant that in the long-term experiment, a higher fre-
quency of CD4+Foxp3+Helios+ was observed in PLNs
of ADMSC-treated mice, suggesting that this increase
could be derived from natural thymic-derived but not
peripherally induced Tregs. In addition, the levels of Th1
cytokines, such as IFN-g, were lower and inversely cor-
related with a high expression of active TGF-b in the pan-
creas of the ADMSC-treated mice 35 days after treatment. It
has been widely demonstrated that TGF-b is an important
suppressor cytokine in the islet compartment for pro-
tection against CD4+ and CD8+ effector lymphocytes
(48). In addition, Tonkin and Haskins (49) showed that
Tregs enter the pancreas during T1D suppression and can
FIG. 8. ADMSC therapy promotes long-term reversion of hyperglycemia in diabetic NOD mice. ADMSCs (1 3 106) were administrated by in-
traperitoneal injection in female NOD diabetic mice (blood glucose >240 mg/dL by two consecutive measurements) on days 0, 7, and 14. A: Blood
glucose (mg/dL) was measured once a week after treatment under nonfasting conditions for 12 weeks. The gray region denotes blood glucose
values <240 mg/dL. Average 6 SEM of blood glucose levels in the initiation of treatment is shown and did not differ between groups (P = NS). The
reversion of hyperglycemia could be maintained for 8 weeks in seven of nine of the ADMSC-treated mice. B: The weekly mean blood glucose levels
of responder mice were signiﬁcantly reduced compared with the untreated group from 2 to 12 weeks. Normoglycemic levels were detected in 57%
(four of seven) of responder mice with no insulin administration. C: Histological analysis of the pancreas by H-E and immunohistochemistry for
insulin expression, respectively. Original magniﬁcation 3200. D: The quantiﬁcation of mononuclear cellular inﬁltrate (or insulitis score) in the
pancreatic islets was determined by counting at least 80 islets/experimental group from at least ﬁve mice/group using the following classiﬁcation:
0 (no cellular inﬁltration), 0–25, 25–50, >50, and 100% of cell inﬁltration in each islet. The frequency of Tregs was analyzed by ﬂow cytometry in
cells obtained from the PLNs of responder mice. The cells were stained for surface markers CD4 and CD25 and afterward for transcription factor
Foxp3. E: Dot plots represent the frequency of CD4+Foxp3+ cells at the CD4+ cell gate. F and G: Frequency of CD4+Foxp3+ and CD4+CD25+Foxp3+
T cells in the CD4+ cell gate, respectively, for each group. H: Dot plots represent the frequency of CD4+Foxp3+Helios+ cells at the CD4+ cell gate.
I and J: Frequency of CD4+Foxp3+Helios2 and CD4+Foxp3+Helios+ in the CD4+ cell gate, respectively. Data are average 6 SEM. *P < 0.05; **P <
0.01. (A high-quality color representation of this ﬁgure is available in the online issue.)
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inhibit effector T cells and macrophages in a TGF-b–dependent
manner.
Herein, ADMSCs were shown to promote the in vitro
expansion of Tregs in a cell-to-cell contact-dependent man-
ner. Previous studies highlight the role of the PD-L1 negative
costimulatory molecule in the development, expansion, and
maintenance of Tregs (33,34). In addition, it has been shown
that bone marrow–derived MSC inhibition of lymphocyte
proliferation is mediated by PD-L1 (50). We showed that
ADMSCs express PD-L1 and promote the in vitro expansion
of CD4+Foxp3+ cells through a mechanism that is partially
mediated by this molecule. In summary, the current study
shows that ADMSC treatment efﬁciently modulated the
CD4+ T cell–mediated immune response and ameliorated
the recent onset of T1D pathogenesis in diabetic NOD mice
by attenuating the Th1 immune response and favoring the
expansion of Tregs in both short- and long-term periods.
ADMSCs have many advantages over other sources of re-
generative cells, such as high yield, and the procedure for
obtaining the cells is minimally invasive. This work encour-
ages further studies to conﬁrm the safety and therapeutic
potential of ADMSCs as attractive candidates for T1D treat-
ment by exploring their immune regulatory effects.
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